Peer-reviewed veterinary case report
Grapiprant pain relief and safety in dogs with arthritis
By L. Rausch‐Derra et al.·Published in Journal of Veterinary Internal Medicine·2016·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A Prospective, Randomized, Masked, Placebo‐Controlled Multisite Clinical Study of Grapiprant, an EP4 Prostaglandin Receptor Antagonist (PRA), in Dogs with Osteoarthritis
- Species:
- dog
Plain-English summary
A group of 285 dogs with osteoarthritis (OA) were treated with either grapiprant, a medication designed to relieve pain, or a placebo. Owners reported that dogs receiving grapiprant showed significant improvements in pain levels after 28 days compared to those on the placebo. While grapiprant was generally well tolerated, some dogs did experience occasional vomiting. Overall, grapiprant proved to be an effective option for managing pain in dogs with OA, offering a potentially better-tolerated alternative to other treatments.
People also search for: dog osteoarthritis treatment · grapiprant for dogs pain relief · dog pain medication side effects
Abstract
Background This study evaluated the effectiveness and safety of grapiprant for treatment of pain in dogs with osteoarthritis (OA). Hypothesis/Objectives Grapiprant will relieve pain as measured by the owner's and veterinarian's evaluation of pain in dogs with OA. Another objective was evaluation of the safety of grapiprant. Animals Two hundred and eighty‐five client‐owned dogs with OA were enrolled and treated with grapiprant or placebo with 262 cases (N = 131 in each group) evaluable for the effectiveness analysis. Methods In this prospective, randomized, masked, placebo‐controlled study dogs were treated daily with grapiprant (2 mg/kg) per OS or placebo. Owners completed an evaluation using the Canine Brief Pain Inventory (CBPI) on days 0, 7, 14, 21, and 28. Success was defined as improvement in the CBPI. Veterinary assessments were made on screening and days 14 and 28. Safety was evaluated by physical examination, evaluation of clinical pathology results, and owner observations. Results Grapiprant treatment improved pain compared to placebo on day 28 (48.1 and 31.3% treatment successes respectively; P = .0315). The pain interference score (PIS) and pain severity score (PSS) improved in the grapiprant group compared to placebo (P = .0029 and 0.0022, respectively). Veterinary assessments were significantly better in the grapiprant‐treated dogs (P = .0086). Grapiprant generally was well tolerated, but a higher percentage of treated dogs (17.02%) had occasional vomiting as compared to the placebo group (6.25%). Conclusions and Clinical Importance Grapiprant is an effective treatment for alleviation of pain in dogs with OA, and represents a modality of treatment that may be better tolerated than current options.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/27075237